Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

Long-term high-intensity interval training may reduce the risk for the decline of kidney function in older adults, a study ...

By: Dr. Suresh D.R., Chief of Laboratory - Centralab Metropolis, Karnataka, and Regional COL - Andhra Pradesh and Telangana, ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Weight fluctuation was associated with a greater risk for diabetic kidney disease progression among individuals with type 1 diabetes.

During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.

Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

Checkpoint Therapeutics gains approval for cosibelimab but faces financial challenges and tough competition. Learn more about ...